

# UCSF

## UC San Francisco Previously Published Works

### Title

Demographic and clinical features of neuromyelitis optica: A review.

### Permalink

<https://escholarship.org/uc/item/1n60d577>

### Journal

Multiple sclerosis (Houndmills, Basingstoke, England), 21(7)

### ISSN

1352-4585

### Authors

Pandit, L

Asgari, N

Apiwattanakul, M

et al.

### Publication Date

2015-06-01

### DOI

10.1177/1352458515572406

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

# Demographic and clinical features of neuromyelitis optica: A review

Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, Kleiter I and Chitnis T; the GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica<sup>S</sup>

**Abstract:** The comparative clinical and demographic features of neuromyelitis optica (NMO) are not well known. In this review we analyzed peer-reviewed publications for incidence and prevalence, clinical phenotypes, and demographic features of NMO. Population-based studies from Europe, South East and Southern Asia, the Caribbean, and Cuba suggest that the incidence and prevalence of NMO ranges from 0.05–0.4 and 0.52–4.4 per 100,000, respectively. Mean age at onset (32.6–45.7) and median time to first relapse (8–12 months) was similar. Most studies reported an excess of disease in women and a relapsing course, particularly in anti-aquaporin 4 antibody (anti AQP4-IgG)-positive patients. Ethnicity may have a bearing on disease phenotype and clinical outcome. Despite limitations inherent to the review process, themes noted in clinical and demographic features of NMO among different populations promote a more global understanding of NMO and strategies to address it.

**Keywords:** NMO, epidemiology, demographics, incidence, prevalence

Date received: 26 November 2014; accepted: 4 January 2015

## Introduction

Neuromyelitis optica (NMO) is an autoimmune inflammatory disorder of the central nervous system that predominantly targets the optic nerve and spinal cord. Until recently, NMO was thought to be a clinical variant of multiple sclerosis (MS). However, clinical features, neuroimaging, immunological, and histopathological characteristics have now been identified which distinguish NMO from MS. Clifford and Gault summarized the salient features of the disease in 1894, though descriptions of the disease appeared much earlier. The typically long spinal cord segmental involvement, longitudinally extensive transverse myelitis (LETM) and neutrophilic pleocytosis in the cerebrospinal fluid (CSF) became incorporated into the first Wingerchuk diagnostic criteria for NMO in 1999.<sup>1</sup> Subsequently, the discovery of anti AQP4-IgG<sup>2</sup> led to the revised Wingerchuk criteria in 2006.<sup>3</sup> The term “NMO spectrum disorders”<sup>4</sup> (NMOSD) encompasses forms of NMO that do not satisfy the 2006 criteria. Examples include isolated unilateral or simultaneous bilateral or recurrent optic neuritis (ON); isolated or recurrent transverse myelitis (TM); typical NMO brain lesions (hypothalamus, corpus callosum, brainstem, periventricular) with or without detectable anti AQP4-IgG autoantibody. Thus, the diagnostic criteria have been refined and the spectrum

of clinical manifestations in NMO has expanded in recent years.

NMO occurs worldwide in diverse races and cultures; however, the global incidence and prevalence of this disease is incompletely characterized. More specifically, it is unclear whether disease frequency, clinical course, severity, and gender predominance vary between geographical regions. Obtaining epidemiological and demographic data for a relatively uncommon disorder like NMO is challenging. Very few published reports of NMO have appeared from emerging nations. Access to magnetic resonance imaging (MRI) centers varies, as do laboratory facilities for CSF analysis and anti AQP4-IgG detection. Hence, timing of the MRI after an attack of myelitis and blood sampling for anti AQP4-IgG testing may vary. Furthermore, lack of uniformity of survey methods, disease definitions, and diagnostic criteria complicate interpretation of the literature.

A small proportion of patients with NMO are seronegative for anti AQP4-IgG, and may represent a heterogeneous spectrum of NMO or disease mimics (including MS and other diseases such as sarcoidosis and paraneoplastic disorders). Thus, studies that include all clinically defined NMO patients are

Multiple Sclerosis Journal

2015, Vol. 21(7) 845–853

DOI: 10.1177/  
1352458515572406



© The Author(s), 2015.  
Reprints and permissions:  
[http://www.sagepub.co.uk/  
journalsPermissions.nav](http://www.sagepub.co.uk/journalsPermissions.nav)

Correspondence to:

**Dr Lekha Pandit MD DM, PhD**

Professor of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, Karnataka, 575018, India.  
[panditmng@gmail.com](mailto:panditmng@gmail.com)

**Pandit L**

KS Hegde Medical Academy, Nitte University, Mangalore, Karnataka, India

**Asgari N**

Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, and Department of Neurology, Vejle Hospital, Denmark

**Apiwattanakul M**

Prasat Neurological Institute Bangkok, Thailand

**Palace J**

**Leite MI**  
Department of Clinical Neurology, Oxford University Hospitals, Oxford, UK

**Paul F**

Neuro Cure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany

**Kleiter I**

Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany

**Chitnis T**

Department of Neurology, Brigham and Women's Hospital and Massachusetts General Hospital, Boston, USA

difficult to compare with those selecting only anti AQP4-IgG-positive patients. In addition, assays for detection of anti AQP4-IgG vary with regard to their sensitivity and specificity. Although most contemporary assays perform well in a high-probability patient, when used for population screening the seropositive rate can vary by two-fold or greater between assays of different specificity.<sup>5,6</sup> The initial AQP4-IgG immunofluorescence assay that was developed is the least sensitive.<sup>2,6</sup> The cell-based assay (CBA), although labor intensive and less suited to mass screening, is most sensitive and specific for use in clinical diagnosis.<sup>6,7</sup> Thus, differences in diagnostic criteria and anti AQP4-IgG assays may account for heterogeneity in epidemiologic data, and may explain some of the observed discrepancies in interpretation.

The goal of this review article is to assess major epidemiological and hospital-based studies to estimate incidence and prevalence of NMO in different geographic regions, and to provide insights into the differences and similarities of demographic and clinical features of NMO among diverse populations.

### Methods

In this paper, we reviewed the published reports of population-based studies, hospital-based retrospective chart reviews, and data from NMO registries. We queried the PubMed database from the years 1999–2014. The search terms used included “neuromyelitis optica”, “Devic’s disease”, “incidence”, “prevalence”, “epidemiology”, “demography” and “clinical features”. In total, 48 studies were examined. Of these, seven population-based epidemiological studies (Table 1) and nine hospital-based studies were included for comparative analysis of clinical and demographic features (Table 2). All studies that were included had utilized Wingerchuck 1999 or 2006 criteria, and results of anti AQP4 - IgG testing were available. Lastly, to integrate a global demographic perspective, selected data obtained from the Atlas of MS 2013 ([www.atlasofms.org](http://www.atlasofms.org)) were also included in the analysis.

### Population-based studies

While data from population-based studies are likely to be more robust, several factors make direct comparisons across such studies challenging. For example, variability in the source data (e.g. clinic, health insurance data, or population based), diagnostic criteria, inclusion of seronegative individuals, definition of NMOSD, and the particular anti AQP4-IgG assay used are important factors undoubtedly influencing

the results. The ethnic mix of the populations studied may also influence the prevalence rates. In addition, most published studies have focused on adults.

### Incidence

There have been several recent studies from Denmark, West Indies, Cuba, the UK, and Austria from which unadjusted incidence rates (per 100,000) could be calculated (Table 1).<sup>8–12</sup> In a Danish population comprising 99% whites, an incidence rate of 0.40 (95%CI 0.30–0.54) was found to be the highest among the five studies included.<sup>8</sup> A French West Indies study<sup>9</sup> found that the age and sex-standardized incidence was 0.22 (95%CI 0.04–0.38), and remained consistent between 1992 and 2007. While the latter study included only NMO cases in which Wingerchuck criteria were fully met, the Danish study included all individuals carrying the diagnosis of NMO, regardless of whether they met these criteria. Thus, selection criteria may influence incidence rates of the disease. A Cuban study included white subjects of Spanish descent, African, and those of mixed racial origins.<sup>10</sup> Here, an overall incidence rate of 0.05 was observed, and was similar across ethnic groups, but varied from 0.12–1.76 across geographical regions of Cuba. The incidence rate in Merseyside, UK, a population consisting of 88% whites, was found to be 0.08 (95%CI 0.03–0.16).<sup>11</sup> An Austrian study<sup>12</sup> reported an incidence rate of 0.05 (95% CI 0.01–0.31), in an all-white population.

### Prevalence

Several studies have measured prevalence (per 100,000) in NMO. The prevalence was 4.4 in Denmark<sup>8</sup> (95%CI 3.1–5.7), 1.96 among the white population of Wales,<sup>13</sup> 0.72 in Merseyside, UK,<sup>11</sup> 2.3 in the French West Indies<sup>9</sup> and 0.52<sup>10</sup> in Cuba. The vast majority of patients in an NMOSD cohort in Austria<sup>12</sup> (71/73, all whites) were seropositive. The prevalence rate of NMO was 0.77 per 100,000.<sup>12</sup> Prevalence data are also available from Japan and India. In Japan, a prevalence rate of 0.9 per 100,000 (95%CI 0.2–2.5) was determined,<sup>14</sup> while in southern India it was 2.7/100,000.<sup>15</sup> Collectively, these studies suggest a relatively wide range in prevalence, including differences in geographic and ethnic cohorts. The Danish study was the only one that included limited forms of NMO.

### Hospital-based studies

Nine hospital-based observational studies were identified (Table 2), four from Europe,<sup>12,16–18</sup> one each from

**Table 1.** Comparative Incidence and prevalence of NMO from recently published studies.

Country	Diagnostic criteria	Source of data	No of cases/population at risk	Ethnicity	Crude incidence/100,000	Crude prevalence/100,000	F/M
French West Indies Cabre <i>et al.</i> , <sup>9</sup> 2007/2009	Wingerchuk 1999, 2006	Hospitals, clinics, neurologists, other specialists, registry, patient association	20/ 683,000	Afro-Caribbean Hispanic	0.19 (0.15–0.23)	2.53	All female
Cuba Cabrera Gomez <i>et al.</i> , <sup>10</sup> 2009	Wingerchuk 1999	Hospitals, clinics, other specialists, neurologists, clinical trial data, MS data base, media	11/111,177,743	Caucasian Afro- Caribbean	0.053 (0.04–0.07)	0.54 (0.39–0.69)	7.3:1
Denmark Asgari <i>et al.</i> , <sup>8</sup> 2011	Wingerchuk 2006	National Registry, Hospitals, MS-clinics, neurologists, other specialists, administrative databases	42/952,000 NMO=36, NMOSD=6	99% Caucasian	0.04	4 (3.1–5.7)	2.8:1
Wales Cossburn <i>et al.</i> , <sup>13</sup> 2012	Wingerchuk 2006	Hospital records, Neurologists, Regional database, Lab records	14/717,572 NMO=11, NMOSD=3	100% Caucasian	–	1.96 (1.22–2.97)	6:1
Japan Houzen <i>et al.</i> , <sup>14</sup> 2012	Wingerchuk 2006	Inpatient and outpatient records of MS-related institutions	3/352,353	Japanese	NA	0.9 (0.2–2.5)	All female
UK Jacob <i>et al.</i> , <sup>11</sup> 2013	Wingerchuk 2006	Hospital records, regional general hospital records, lab records	8/1,145,322 NMO=5 NMOSD=3	Caucasian 7 (88%) African 1(12%)	0.08 (0.03–0.16)	0.72 (0.3–0.16)	3.5:1
India Pandit <i>et al.</i> , <sup>15</sup> 2014	Wingerchuk 2006	Disease registry, inpatient and outpatient records of teaching hospitals and clinics, MRI centers	11/ 419,306	South Indians	NA	2.6	1.2:1

**Table 2.** Clinical and demographic features of NMO#.

Country/ study	Wingerchuk diagnostic criteria	Cases selected	Total cases & gender (F/M)	Ethnicity	Mean Age at onset & range	Median time to 1 <sup>st</sup> relapse (months)	First attack	AQP4* IgG +ve	Median follow-up	Median EDSS	Mortality disease related
French West Indies Cabre et al., <sup>9</sup> 2007/2009	Wingerchuk 1999, 2006	NMO	96 (88F/8M)	Hispanic Afro-Caribbean	29.5 (11–74)	11.5 (1–300)	NA	32%	9.5 (1–40) years	NA	24 (25%)
Brazil Bichueti, <sup>20</sup> 2009	1999, 2006	NMO relapsing	41 (29F/ 12M)	NA	32.6 (20–60)	NA	TM 41% ON 34% ON+TM 24%	41%	52 (7–200) months	NA	4 (14.3%)
France Collongues et al., <sup>16</sup> 2010	2006	NMO, NMOSD	125 (94F/31M)	White=87% other=13%	34.7 (4–66)	12 (30.8–43.1)	TM 45.6% ON 36.8%	54%	8.7 (0.1–39.5) years	NA	4 (3.2%)
Denmark Asgari et al., <sup>8</sup> 2011	2006	NMO, NMOSD	42 (31F/11M)	White=99%	35.6 (15–64)	NA	TM 59.5% ON 35.7%	62.0%	6.5 (2–10) years	6.5 (1.0–9)	3 (7.1%)
Germany Jarius et al., <sup>17</sup> 2012	2006	NMO, NMOSD	175 (150F/25M)	White = 100%	39 (10–81)	8.5 (1–216)	ON 58% ON+TM 8%	78.3%	4.8 (0–390) months	6.5 (1.5–10)	5 (2.9%)
USA Mealy et al., <sup>19</sup> 2012	2006	NMO, NMOSD	187(162F/25M)	White=89 AA=69 other=29	40	NA	TM 50.2% ON 35.3%	66.6%	5.5 (0.2–38) months	NA	NA
Korea Kim et al., <sup>22</sup> 2012	2006	NMO, NMOSD	106 (97F/9M)	Korean=100%	NA	5 (1–74)	NA	100%	7.0 (1–24) years	NA	NA
India Pandit et al., <sup>21</sup> 2013	2006	NMO, NMOSD	70(30F/40M)	South Indians-100%	37.5 (12–65)	12 (4–96)	NA	39%	4.5 (1–13) years	5.5 (1.5–10)	12 (17%)
Austria Aboul-Enein et al., <sup>12</sup> 2013	1999, 2006 (all seropositive)	NMO, NMOSD	73 (63/10)	White=100%	45.7 (12.3–79.6)	NA	ON 54.2% TM 41.7% ON+TM 4.2%	97% (71/73)	NA	NA	NA
Spain Höfberger et al., <sup>18</sup> 2014	2006	NMO	48 (41F/7M)	White=94% Other=6%	38 (18–73.5)	8.3 (1–144)	TM 36% ON 29%; ON+TM 33%	81%	69 (1–415) months	3.8 (0–10)	2 (4.2%)

AF: African; AS: Asian; AA: African American; ON: optic neuritis; TM: transverse myelitis; ARR: annualized relapse rate; NA: not available.  
 \*percentage of patients who were AQP4-IgG positive among those tested.  
 #Used either Wingerchuk 1999 or 2006 criteria, all others used Wingerchuk 2006 alone.

the USA,<sup>19</sup> Brazil,<sup>20</sup> Austria,<sup>12</sup> India,<sup>21</sup> and Korea.<sup>22</sup> All of these studies used Wingerchuk 2006 diagnostic criteria except the Spanish<sup>18</sup> study (which used 1999 and 2006 criteria). Median time to second attack was 8–12 months (range 1–216 months). Mortality ranged from 2.9–25% and was disease related in the majority of cases. Analysis of registry-based data suggests that the proportion of patients with NMO among all demyelinating disorders varies significantly among different geographic regions: 1.2% in Italy,<sup>23</sup> 1–2% in the USA,<sup>19</sup> 13.7% in India,<sup>21</sup> and 39.3% in Thailand.<sup>24</sup> The study from Thailand underscores the need for supportive radiological criteria that justify the clinical diagnosis. Several anti AQP4-IgG seropositive patients with a diagnosis of MS, in retrospect had radiological and clinical features of NMO.

### Effect of age

There are geographic differences with respect to NMO and patient age. From prevalence studies, median age at onset was found to be 30.5 years in Cuba,<sup>10</sup> 39.5 years in South East Wales,<sup>13</sup> 30 years in Denmark,<sup>8</sup> and 55.2 years in Austria.<sup>12</sup> These differences may reflect variations in case ascertainment and diagnostic criteria, access to medical care, and/or ethnicity. In the Cuban study, blacks were older than non-blacks at disease onset; however, there were no differences between other subgroups.<sup>10</sup> The mean age of onset of NMO ranged from 32.6–45.7 years in major case series (Table 2). In a study comparing seropositive individuals (based on the CBA) in the UK, and Japan, Afro-Caribbeans experienced earlier disease onset than white and Asian patients.<sup>24</sup> Pediatric onset is rare, with <5% of cases presenting prior to age 18 in two studies.<sup>25,26</sup> In contrast, late-onset NMO/NMOSD, defined as onset age >50 years, accounted for 108/430 (25%) in a large multicenter cohort study.<sup>27</sup> Compared with patients with adult-onset NMO, those with pediatric NMO more frequently have brain involvement, experience milder locomotor disability, and develop significantly earlier visual disability.<sup>25</sup> In a German study that contrasted clinical presentation of seropositive and negative NMO patients, the proportion of anti-AQP4-IgG-positive patients appeared to increase with age; however, mean age at onset did not differ among seronegative and seropositive patients.<sup>17</sup> The largest study assessing serological status and age is that from the Mayo clinic, which compared the demographics of over 50,000 patients referred for NMO-IgG testing.<sup>26</sup> Similar to the German study,<sup>17</sup> the proportion of seropositive females was shown to increase with age, and was highest in the >65 year-old group, accounting for 12% of the entire seropositive cohort.

### Gender ratio

As with many autoimmune diseases, NMO and NMOSD are more common in females, ranging from 66–88% of the patient population.<sup>8,9,16</sup> One study reported an 89% female predominance when including only cases with relapsing NMO. Even prior to the discovery of anti AQP4-IgG, relapsing NMO was known to be more prevalent in females (83%), whereas a more equal female/male distribution was detected in monophasic disease (48%). Anti AQP4-IgG positivity was associated with relapsing disease with rates of 81–91%,<sup>17,28</sup> particularly when CBA is used. Among patients with LETM, females represent 86% of anti AQP4-IgG seropositive compared with 44% of seronegative individuals.<sup>29</sup> The variation across studies may be influenced by limited patient numbers in those conducted within specialized centers. Moreover, there may be racial and geographical effects. For example, in a comparative study from different populations<sup>24</sup> females represented 82% of patients in whites from the UK, compared with 75% in Afro-Caribbeans and 98% in a Japanese cohort. In an all-white Austrian cohort, the female ratio was 87% for all AQP4-IgG-positive patients<sup>12</sup> while it reached 100% in a French West Indian cohort.

### Disease onset, course and severity

Several multicenter registry-based observational, retrospective studies (Table 2) provide information about clinical course and disease severity. Some common findings emerged from these studies. The presenting symptom was usually either ON or TM, especially among seropositive patients. Simultaneous TM and ON, bilateral ON, and monophasic course were relatively more common presentations among seronegative patients.<sup>16,17, 29</sup> Males and females were similarly affected in this subgroup.<sup>17,29</sup> Age at disease onset appears to have a bearing on disability type. In a comparative study, Kitley *et al.*<sup>25</sup> found that patients in the UK had young-onset disease commonly presenting with ON and had a high risk of visual disability. An older age of onset was significantly associated with motor disability, in both Japanese and UK cohorts. Jarius *et al.*<sup>17</sup> have further identified distinct clinical features for NMO patients based on anti AQP4-IgG serological status. Seropositive women had more severe clinical attacks than males in this cohort, as evidenced by high lesion load in the spinal cord and other types of co-existing autoimmunity. Overall, seropositive and seronegative patients did not differ in terms of age of onset, time to relapse, relapse rates, rate of Expanded Disability Status Scale (EDSS) progression, and mortality rate. Irrespective of anti AQP4-IgG serological status, predictors of



outcome included development of tetraparesis during the first attack of TM, and multiple attacks of TM in the first year. Distribution of brain lesions was different depending on anti AQP4-IgG status. Periaqueductal grey matter, hypothalamic, and area postrema lesions may be more often seen in seropositive patients.<sup>30</sup> In the Danish study, NMO-IgG seropositive patients frequently developed brainstem lesions and LETM during the decade of follow-up.<sup>31</sup> A study from Barcelona, which focused on LETM, found that EDSS at presentation was predictive of the recurrence risk and disability.<sup>32</sup>

### Ethnicity and disease course

Ethnicity appears to be an influential factor in NMO and NMOSD. In the Cuban study<sup>10</sup> patients of African origin were older, had more relapses, abnormalities in brainstem-evoked potentials, and acquired more lesions on brain MRI than comparator patients. African Americans in the US<sup>18</sup> had significantly more brainstem MRI abnormalities than white Americans. Kitley and colleagues<sup>25</sup> compared the disease course and prognostic factors for seropositive NMO patients in the UK ( $n=59$ ) and Japan ( $n=47$ ). In the UK group, 45/59 were white, 12/59 were Afro-Caribbean, and two were Asian. Age of onset and ethnicity were associated with outcome. Young white patients presented with ON, and had greater visual disability. In contrast, older patients of both ethnicities presented with myelitis and greater motor disability. The Afro-Caribbean subgroup was significantly younger at onset than both white and Japanese patients (mean  $28.0 \pm 13.1$  years and  $44.9 \pm 17.2$  years, respectively). Initial events more commonly included those of brain/brainstem in Afro-Caribbean patients compared with white and Japanese, and uniformly had relapsing NMO compared with 80% in the other ethnicities. Annualized relapse rate among Afro-Caribbean patients was comparable with that of white patients but higher than that of the Japanese. Visual disability was more severe in non-white patients. In contrast, white patients had a later age of onset and worse motor outcomes. In the study conducted in Cuba and French West Indies,<sup>9,10</sup> lack of recovery after the first attack and a higher rate of attacks during the first year of disease were strong independent prognostic factors of mortality.

### Population genetics

Initial epidemiological studies have suggested ethnicity-based differences in genetics of NMO patients. However, no specific genetic determinants of NMO disease have thus far been identified. The genetic basis for these ethnic differences is not well understood, but

the human leukocyte antigen (HLA) system remains an obvious candidate. Studies from Japan have analyzed the clinical and genetic features of the optico-spinal form of multiple sclerosis (OSMS), a disease entity which may overlap with NMO. In that population, conventional MS was associated with HLA-DRB1\*1501 whereas OSMS/NMO was associated with HLA DPB1\*0501.<sup>33</sup> Other population studies of HLA in NMO indicate that the DRB1\*0301<sup>34-36</sup> and DRB1\*10<sup>37</sup> alleles are associated with increased risk.

Familial NMO has been described. In the largest study, Matiello et al.<sup>38</sup> identified 12 families (five Asian, four Latino, two African, one white) with a total number of 25 affected individuals, 19 of whom were AQP4-IgG positive. The role of environmental influences in the etiopathogenesis of NMO has not been established. Migration studies are needed to explore whether risk is mutable with migration and how this relates to age at migration.

### Insights into NMO epidemiology from the Atlas of MS Database

In 2013, a questionnaire designed to update the MS global dataset added a number of queries relating to NMO, including prevalence, incidence, gender ratio, mean age of onset, diagnostic criteria used, and therapeutic options. This questionnaire received notifications of 10,567 cases obtained from 40 of 107 countries participating in the survey. Roughly one-third of the patients reported were from Japan (3500), creating potential bias. Data on prevalence (expressed as cases per 100,000) were available from 35 countries. In temperate zones, Central European countries had a prevalence ranging from 0.23 in Belgium to 2.0 in Norway, while Denmark (4.4) and The Netherlands (5) had comparatively high prevalence. By comparison, NMO prevalence among the Japanese population was 2.8. South Africa and Paraguay had the highest prevalence (5), followed by French West Indies (4.2). In the Middle East, the projected figures ranged from 0.16–2 and in South East Asia from 0.43–2.7. These widely disparate reports, particularly among European countries, may have resulted from differing methodologies involved in the collection of source data. No data were available from most regions of the African continent, Eastern Europe, parts of Central America, and South Asia. In each population studied patients were predominantly female, with ratios ranging from 1.0 in Ireland to 10.1 in Paraguay. Overall the mean age of onset ranged from 25.0–45.7 years. The MS database provided information from a variety of countries across the globe. In most instances, the findings were not supported by published literature and

were often sourced from single or few individuals with an interest in the subject. Resource-poor countries had few neurologists and limited MRI centers, and diagnostic NMO-IgG testing was limited or non-existent. These factors hampered the reliability of the survey.

### Conclusions

NMO epidemiology has largely been based on relatively small populations and data from tertiary hospitals. Many of these initial studies have yielded inconsistent findings. Confounding factors include the use of non-standardized diagnostic criteria, variability in assays for anti-AQP4 antibody, inconsistent inclusion of NMO-IgG seronegative patients, small study cohorts, and potential for selection bias. These factors limit the comparative assessment and statistical power of epidemiologic studies in NMO and NMOSD. While differences in ethnicity appear to impact clinical disease course and NMO-IgG status, recent studies have disclosed similarities in incidence and prevalence of NMO. Female predominance is commonly seen and appears congruent with NMO-IgG seropositive status, which itself associates with a relapsing phenotype. HLA haplotype associations have been hypothesized, but the genetic basis for differences in risk, severity, therapeutic efficacy, or clinical outcomes remains uncertain. Larger adequately powered epidemiological studies applying standardized definitions and methodologies are needed before specific conclusions can be drawn. The advent of more specific diagnostic criteria, improved diagnostic assays and methods, and a better understanding of the basic immunology of NMO and NMOSD are likely to advance these goals. In turn, these steps should improve consistency in diagnosis and enhance study cohorts for the most informative clinical trials for NMO.

### Acknowledgements

The authors thank The Guthy-Jackson Charitable Foundation for its support in organizing the NMO International Clinical Consortium & Biorepository.

### Conflict of interest

None declared.

### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### Notes

<sup>§</sup>Members of The Guthy-Jackson Charitable Foundation (GCJF) NMO International Clinical

Consortium and Biorepository (ICC&BR) and the GJCF NMO Biorepository Oversight Committee (BOC) are recognized as affiliated authors of this study and listed below in alphabetic order by institution:

Brigham and Women's Hospital and Massachusetts General Hospital, Boston, USA – Tanuja Chitnis

Catholic University, Rome, Italy – Raffaele Iorio

Charité Universitätsmedizin Berlin, Germany & University Medicine Göttingen, Germany – Jens Würfel

Charité University Medicine Berlin, Berlin, Germany – Friedemann Paul

Department of Neurology, Erasmus MC, Rotterdam – Danielle van Pelt and Rogier Hintzen

Duke University Medical Center, Durham, NC – Thomas Tedder

Hospital Clinic and Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain – Albert Saiz and Pablo Villoslada

Johns Hopkins University, Baltimore, USA – Michael Levy

KS Hegde Medical Academy, Nitte University, Mangalore, India – Lekha Pandit

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA – Eric Klawiter

Mayo Clinic, Rochester, MN, USA – Brian Weinschenker

Mayo Clinic, Scottsdale, AZ, USA – Dean Wingerchuk

National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea – Ho Jin Kim

National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina – Silvia Tenenbaum

Oxford University Hospitals Trust, Oxford, UK – Jacqueline Palace and Maria Isabel Leite

Prasat Neurological Institute Bangkok, Thailand – Metha Apiwattanakul

School of Medicine, Griffith University, Gold Coast Campus, QLD, Australia & Department of Neurology, Gold Coast University Hospital, Southport, QLD, Australia – Simon Broadley

Siriraj Hospital, Mahidol University, Bangkok, Thailand – Naraporn Prayoonwivat

St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany – Ingo Kleiter

St Josef-Hospital Bochum, Bochum, Germany – Kerstin Hellwig

Stanford University School of Medicine, Stanford, CA, USA – May Han

The Children's Hospital of Philadelphia, University of Pennsylvania, USA – Brenda Banwell

The Guthy-Jackson Charitable Foundation, San Diego, CA, USA – Katja Van Herle

The Walton Centre NHS Foundation Trust, Liverpool, UK – Anu Jacob



Thomas Jefferson University, Philadelphia, USA – Craig Hooper  
Tohoku University, Sendai, Japan – Douglas Kazutoshi Sato, Ichiro Nakashima and Kazuo Fujihara  
Universidade Federal de Sao Paulo, Sao Paulo, Brazil – Denis Bichuetti  
Universitat Dusseldorf, Germany – Orhan Aktas  
University Hospital of Strasbourg, Strasbourg, France – Jerome De Seze  
University of California, Los Angeles, CA; and Harbor-UCLA Medical Center, Torrance CA, USA – Michael Yeaman  
University of California San Francisco, USA – Emmanuelle Waubant  
University of California San Francisco, USA – Scott Zamvil  
University of Denver, Colorado, USA – Jeffrey Bennett  
University of Michigan Medical School, Ann Arbor, MI, USA – Terry Smith  
University of Minas Gerais Medical School, Belo Horizonte, Brazil – Marco Lana-Peixoto  
University of Southern Denmark, Denmark and Department of Neurology, Vejle Hospital, Denmark – Nasrin Asgari  
University of Texas Southwestern Medical Center at Dallas, Dallas, USA – Benjamin Greenberg and Olaf Stuve  
Yale University School of Medicine, New Haven, CT, USA – Kevin O'Connor

## References

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica ( Devic's syndrome). *Neurology* 1999; 53: 1107–1114.
2. Lennon V, Wingerchuk D, Kryzer T, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. *Lancet* 2004; 36445: 2106–2112.
3. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. *Neurology* 2006; 66: 1485–1489.
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. *Lancet Neurol* 2007; 6: 805–815.
5. Pittock SJ, Lennon VA, Bakshi N, et al. Seroprevalence of aquaporin-4-IgG in a Northern California population representative cohort of multiple sclerosis. *JAMA Neurol*. 2014; 71: 1433–1436.
6. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. *Neurology* 2012; 78: 665–671.
7. Jarius S and Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: A critical review of the literature. *Brain Pathol* 2013; 23: 661–683.
8. Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians. *Neurology* 2011; 76: 1589–1595.
9. Cabre P. Environmental changes and epidemiology of multiple sclerosis in the French West Indies. *J Neurol Sci* 2009; 286: 58–61.
10. Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, et al. An epidemiological study of neuromyelitis optica in Cuba. *J Neurol* 2009; 256: 35–44.
11. Jacob A, Panicker J, Lythgoe D, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. *J Neurol* 2013; 260: 2134–2137.
12. Aboul-Enein F, Seifert-Held T, Mader S, et al. Neuromyelitis optica in Austria in 2011: To bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. *PLoS One* 2013; 8: e79649.
13. Cossburn M, Tackley G, Baker K, et al. The prevalence of neuromyelitis optica in South East Wales. *Eur J Neurol* 2011; 19: 655–659.
14. Houzen H, Niino M, Hirotani M, et al. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. *J Neurol Sci* 2012; 323: 117–122.
15. Pandit L and Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. *Mult Scler J* 2014; 20: 1651–1653.
16. Collongues N, Marignier R, Zéphir H, et al. Neuromyelitis optica in France: A multicenter study of 125 patients. *Neurology* 2010; 74: 736–742.
17. Jarius S, Ruprecht K, Wildemann B, et al., for the German Neuromyelitis Optica Study Group (NEMOS). Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicenter study of 175 patients. *J Neuroinflammation* 2012; 9: 14.
18. Höftberger R, Sepúlveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. *Mult Scler* 2014; doi:10.1177/1352458514555785 [Epub ahead of print].
19. Mealy M, Wingerchuck D, Greenberg B, et al. Epidemiology of neuromyelitis optica in the United States, a multicenter analysis. *Arch Neurol* 2012; 69: 1176–1180.

20. DB Bichuetti DB, Oliveira EML, Souza NA, et al. Neuromyelitis optica in Brazil: A study on clinical and prognostic factors. *Mult Scler* 2009; 15: 613–619.
21. Pandit L and Mustafa S. Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry. *Ann Ind Academy Neurol* 2013; 16: 572–576.
22. Kim SH, Kim W, Li XF, et al. Clinical spectrum of CNS aquaporin-4 autoimmunity. *Neurology* 2012; 78: 1179–1185.
23. Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. *J Neurol* 2009; 256: 1891–1898.
24. Siritho S, Nakashima I, Takahashi T, et al. AQP4 antibody-positive Thai cases: Clinical features and diagnostic problems. *Neurology* 2011; 77: 827–834.
25. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. *Brain* 2012; 135: 1834–1849.
26. Collongues N, Marignier R, Zephir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. *Neurology* 2010; 75: 1084–1088.
27. Quek AM, McKeon A, Lennon VA, et al. Effects of age and sex on aquaporin-4 autoimmunity. *Arch Neurol* 2012; 69: 1039–1043.
28. Collongues N, Marignier R, Jacob A, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. *Mult Scler* 2013; 20: 1086–1094.
29. Kitley J, Leite MI, Küker W, et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. *JAMA Neurol* 2013; 70: 1375–1378.
30. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. *Neurology* 2013; 80: 2194–2200.
31. Downer JJ, Leite MI, Carter R, et al. Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete? *Neuroradiology* 2012; 54: 279–285.
32. Asgari N, Skejoe HPB, Lillevang ST, et al. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): A population-based, descriptive study. *BMC Neurol* 2013; 13: 33.
33. Sepulveda M, Blanco Y, Rovira A, et al. Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. *Mult Scler* 2013; 19: 742–748.
34. Matsushita T, Matsuoka T, Isobe N, et al. Association of the HLA-DPB1\*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. *Tissue Antigens* 2009; 73: 171–176.
35. Brum DG, Barreira AA, dos Santos AC, et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. *Mult Scler* 2010; 16: 21–29.
36. Deschamps R, Paturel L, Jeannin S, et al. Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population. *Mult Scler* 2011; 17: 24–31.
37. Zephir H, Fajardy I, Outteryck O, et al. Is neuromyelitis optica associated with human leukocyte antigen? *Mult Scler* 2009; 15: 571–579.
38. Matiello M, Kim HJ, Kim W, et al. Familial neuromyelitis optica. *Neurology* 2010; 75: 310–315.